Literature DB >> 12673517

[Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology].

H Riechelmann1, C Bachert, O Goldschmidt, B Hauswald, L Klimek, W W Schlenter, A J Tasman, M Wagenmann.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12673517     DOI： 10.1055/s-2003-38411

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN： 0935-8943            Impact factor:   1.057


× No keyword cloud information.
  20 in total

1.  [Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].

Authors:  U Förster-Ruhrmann; W Behrbohm; G Pierchalla; A J Szczepek; J W Fluhr; H Olze
Journal:  HNO       Date:  2019-08       Impact factor: 1.284

Review 2.  [Analgesic intolerance (AI). Key position of ENT physicians for early detection of this condition].

Authors:  U Förster; H Olze
Journal:  HNO       Date:  2008-04       Impact factor: 1.284

3.  Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis.

Authors:  Zheng Zhu; Yanqing Xie; Weijie Guan; Yi Gao; Rongquan Huang; Shu Xia; Wenhua Jian; Zhiyu Liang; Jinping Zheng
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

4.  Tropomyosin sensitization in house dust mite allergic patients.

Authors:  Sven Becker; Moritz Gröger; Martin Canis; Elisabeth Pfrogner; Matthias F Kramer
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

5.  Leukotriene D4 nasal provocation test: Rationale, methodology and diagnostic value.

Authors:  Zheng Zhu; Yanqing Xie; Weijie Guan; Y I Gao; Shu Xia; Jianxin Liang; Jinping Zheng
Journal:  Exp Ther Med       Date:  2016-05-10       Impact factor: 2.447

6.  IgE reactivity profiles among house dust mite allergic patients in Bavaria.

Authors:  Sven Becker; Matthias F Kramer; Miriam Havel; Christian Welz; Sabine Markmann; Moritz Gröger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-30       Impact factor: 2.503

7.  Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.

Authors:  Gabriela Senti; Bettina M Prinz Vavricka; Iris Erdmann; Mella I Diaz; Richard Markus; Stephen J McCormack; John J Simard; Brunello Wüthrich; Reto Crameri; Nicole Graf; Pål Johansen; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

8.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

9.  Effect of pollen-specific sublingual immunotherapy on oral allergy syndrome: an observational study.

Authors:  Karl-Christian Bergmann; Hendrik Wolf; Jörg Schnitker
Journal:  World Allergy Organ J       Date:  2008-05       Impact factor: 4.084

10.  Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial.

Authors:  Ludger Klimek; Claus Bachert; Karl-Friedrich Lukat; Oliver Pfaar; Hanns Meyer; Annemie Narkus
Journal:  Clin Transl Allergy       Date:  2015-08-03       Impact factor: 5.871
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.